Actavis Pharma is the world’s third-largest generic pharmaceutical company. The Company has commercial operations in more than 60 key markets, a broad product line consisting of multiple dosage forms a strong position in generic oncology injectables and an expanded OTC presence.

Our portfolio includes generics products we have developed internally, products we have licensed from third parties and products we distribute for third parties.

In the U.S., the Company’s generics business is focused on maintaining a leading position within the U.S. generics market, where it holds approximately 10% market share.

Outside the U.S., the Company has expanded in key markets throughout the Americas, Europe, and Middle East/Africa/Asia-Pacific (MEAAP), entered new, growing markets and diversified its business into a truly global company.